Cibc World Markets Corp purchased a new position in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 3,445 shares of the company's stock, valued at approximately $291,000.
Other hedge funds also recently bought and sold shares of the company. Corient Private Wealth LLC bought a new position in shares of Axsome Therapeutics in the 4th quarter valued at about $239,000. Royce & Associates LP raised its position in Axsome Therapeutics by 64.4% during the fourth quarter. Royce & Associates LP now owns 37,000 shares of the company's stock valued at $3,131,000 after purchasing an additional 14,500 shares during the period. Swiss National Bank lifted its stake in shares of Axsome Therapeutics by 1.5% in the 4th quarter. Swiss National Bank now owns 61,400 shares of the company's stock valued at $5,195,000 after purchasing an additional 900 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new position in shares of Axsome Therapeutics in the 4th quarter worth approximately $6,219,000. Finally, HighTower Advisors LLC purchased a new stake in Axsome Therapeutics during the 4th quarter valued at $1,139,000. Hedge funds and other institutional investors own 81.49% of the company's stock.
Insider Transactions at Axsome Therapeutics
In other Axsome Therapeutics news, CFO Nick Pizzie sold 3,000 shares of Axsome Therapeutics stock in a transaction on Friday, February 14th. The shares were sold at an average price of $131.07, for a total value of $393,210.00. Following the transaction, the chief financial officer now directly owns 42,187 shares of the company's stock, valued at approximately $5,529,450.09. The trade was a 6.64 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 22.40% of the company's stock.
Axsome Therapeutics Stock Down 1.6 %
Axsome Therapeutics stock traded down $1.92 during mid-day trading on Wednesday, reaching $118.45. 323,128 shares of the company were exchanged, compared to its average volume of 921,955. Axsome Therapeutics, Inc. has a 12-month low of $64.11 and a 12-month high of $139.13. The business has a fifty day moving average of $118.07 and a 200 day moving average of $100.65. The firm has a market cap of $5.78 billion, a P/E ratio of -19.77 and a beta of 1.00. The company has a debt-to-equity ratio of 3.22, a quick ratio of 2.04 and a current ratio of 2.11.
Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last issued its quarterly earnings data on Tuesday, February 18th. The company reported ($0.96) earnings per share for the quarter, beating analysts' consensus estimates of ($0.97) by $0.01. The company had revenue of $118.77 million for the quarter, compared to the consensus estimate of $117.83 million. Axsome Therapeutics had a negative return on equity of 223.51% and a negative net margin of 74.47%. Research analysts anticipate that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.
Wall Street Analyst Weigh In
Several equities research analysts have recently weighed in on the stock. Needham & Company LLC reissued a "buy" rating and issued a $153.00 target price on shares of Axsome Therapeutics in a research note on Monday, March 3rd. William Blair reiterated an "outperform" rating on shares of Axsome Therapeutics in a report on Tuesday, February 18th. Wells Fargo & Company raised their price objective on shares of Axsome Therapeutics from $140.00 to $160.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 12th. Morgan Stanley raised their price target on Axsome Therapeutics from $125.00 to $190.00 and gave the stock an "overweight" rating in a research note on Thursday, February 27th. Finally, Deutsche Bank Aktiengesellschaft initiated coverage on Axsome Therapeutics in a research report on Tuesday, February 11th. They issued a "buy" rating and a $176.00 price objective on the stock. One research analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $167.36.
Read Our Latest Stock Analysis on Axsome Therapeutics
About Axsome Therapeutics
(
Free Report)
Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.
Featured Stories
Before you consider Axsome Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Axsome Therapeutics wasn't on the list.
While Axsome Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
